SCHEMBL25797127

SCHEMBL25797127

CCOc1cc([N+](=O)[O-])ccc1N1CC2CC1CN2C(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 3/20 0.44
▸ RET P07949 2/20 0.43
▸ HSD11B1 P28845 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ LMNA P02545 3/20 0.40
▸ MAPT P10636 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ HDAC1 Q13547 1/20 0.39
▸ PARP1 P09874 1/20 0.39
▸ GABRA1 P14867 1/20 0.38
▸ GABRG2 P18507 1/20 0.38
▸ GABRB3 P28472 1/20 0.38
▸ GABRA5 P31644 1/20 0.38
▸ GABRA3 P34903 1/20 0.38
▸ GABRA2 P47869 1/20 0.38
▸ GABRA6 Q16445 1/20 0.38
▸ MEN1 O00255 3/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ F13A1 P00488 1/20 0.37
▸ TGM2 P21980 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18186327 0.89 HSD11B1 (0.43) GPR119RETHSD11B1ALDH1A1LMNA
SCHEMBL18186328 0.89 HSD11B1 (0.43) GPR119RETHSD11B1ALDH1A1LMNA
SCHEMBL25797144 0.88 GPR119 (0.49) GPR119HSD11B1ALDH1A1LMNAMAPT
SCHEMBL25797111 0.87 HSD11B1 (0.41) GPR119RETHSD11B1ALDH1A1LMNA
SCHEMBL25797157 0.87 HSD11B1 (0.41) GPR119RETHSD11B1ALDH1A1LMNA
SCHEMBL25797118 0.86 HSD11B1 (0.41) GPR119RETHSD11B1ALDH1A1LMNA
SCHEMBL18186221 0.85 HSD11B1 (0.44) GPR119RETHSD11B1ALDH1A1LMNA
SCHEMBL18186222 0.85 HSD11B1 (0.44) GPR119RETHSD11B1ALDH1A1LMNA
SCHEMBL18186329 0.85 HSD11B1 (0.44) GPR119RETHSD11B1ALDH1A1LMNA
SCHEMBL18186374 0.85 GPR119 (0.45) GPR119RETHSD11B1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203042-A1 COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS NANJING RUIJIE PHARMA CO., LTD. (CN) 2023-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203042-A1 COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS SYK, BTK, LCK GPR119 792/4885RET 539/4885HSD11B1 1700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback